DEBRICHEM
Commercial- Indications
- Chronic wounds, Hard-to-heal wounds, Infected wounds
Company intelligence / Profile preview
DEBx Medical has developed and commercialized a disruptive device-based solution for the rapid removal of infection and biofilm in hard-to-heal/chronic wounds. Its lead product, DEBRICHEM®, can remove infection and biofilm within seconds with a single application. Clinical evidence shows visible results within days, improving healing rates and reducing patient discomfort. Thousands of patients have already benefited globally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DEBx Medical.